151 related articles for article (PubMed ID: 37034398)
1. Intrauterine contraceptive discontinuation reasons among female trial participants living with HIV in Cape Town, South Africa: A qualitative analysis.
Pradhan S; Tolley EE; Langwenya N; Jones HE; Hoover DR; Petro G; Myer L; Todd CS
Front Glob Womens Health; 2023; 4():1010794. PubMed ID: 37034398
[TBL] [Abstract][Full Text] [Related]
2. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
Todd CS; Jones HE; Langwenya N; Hoover DR; Chen PL; Petro G; Myer L
PLoS Med; 2020 May; 17(5):e1003110. PubMed ID: 32442189
[TBL] [Abstract][Full Text] [Related]
3. Canadian Contraception Consensus (Part 3 of 4): Chapter 7--Intrauterine Contraception.
Black A; Guilbert E; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman W; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; Mansouri S
J Obstet Gynaecol Can; 2016 Feb; 38(2):182-222. PubMed ID: 27032746
[TBL] [Abstract][Full Text] [Related]
4. Effect of vaginal administration of misoprostol before intrauterine contraceptive insertion following previous insertion failure: a double blind RCT.
Bahamondes MV; Espejo-Arce X; Bahamondes L
Hum Reprod; 2015 Aug; 30(8):1861-6. PubMed ID: 26040478
[TBL] [Abstract][Full Text] [Related]
5. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
French R; Van Vliet H; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Helmerhorst F; Guillebaud J
Cochrane Database Syst Rev; 2004; 2004(3):CD001776. PubMed ID: 15266453
[TBL] [Abstract][Full Text] [Related]
6. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
Modesto W; Bahamondes MV; Bahamondes L
Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
[TBL] [Abstract][Full Text] [Related]
7. Contraceptive method preference and reasons for contraceptive discontinuation among women randomized to intramuscular depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant: Findings from Durban, South Africa.
Beesham I; Bosman S; Beksinska M; Scoville CW; Smit J; Nanda K
Contraception; 2022 Apr; 108():37-43. PubMed ID: 34848180
[TBL] [Abstract][Full Text] [Related]
8. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
9. Adolescent Experiences With Intrauterine Devices: A Qualitative Study.
Schmidt EO; James A; Curran KM; Peipert JF; Madden T
J Adolesc Health; 2015 Oct; 57(4):381-6. PubMed ID: 26126950
[TBL] [Abstract][Full Text] [Related]
10. Acceptability of intrauterine contraception among women living with human immunodeficiency virus: a randomised clinical trial.
Kakaire O; Tumwesigye NM; Byamugisha JK; Gemzell-Danielsson K
Eur J Contracept Reprod Health Care; 2016 Jun; 21(3):220-6. PubMed ID: 26895345
[TBL] [Abstract][Full Text] [Related]
11. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
12. Safety of insertion of the copper IUD and LNG-IUS in nulliparous women: a systematic review.
Foran T; Butcher BE; Kovacs G; Bateson D; O'Connor V
Eur J Contracept Reprod Health Care; 2018 Oct; 23(5):379-386. PubMed ID: 30382754
[TBL] [Abstract][Full Text] [Related]
13. A survey of young women's perceptions of the influence of the Levonorgestrel-Intrauterine System or copper-intrauterine device on sexual desire.
Malmborg A; Brynhildsen J; Hammar M
Sex Reprod Healthc; 2019 Oct; 21():75-80. PubMed ID: 31395237
[TBL] [Abstract][Full Text] [Related]
14. Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
French R; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Guillebaud J
Cochrane Database Syst Rev; 2001; (2):CD001776. PubMed ID: 11406007
[TBL] [Abstract][Full Text] [Related]
15. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
[TBL] [Abstract][Full Text] [Related]
16. Hormonal and intrauterine methods for contraception for women aged 25 years and younger.
Krashin J; Tang JH; Mody S; Lopez LM
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD009805. PubMed ID: 26280888
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.
Simonatto P; Bahamondes MV; Fernandes A; Silveira C; Bahamondes L
J Obstet Gynaecol Res; 2016 May; 42(5):554-9. PubMed ID: 26817571
[TBL] [Abstract][Full Text] [Related]
18. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.
Luukkainen T; Allonen H; Haukkamaa M; Holma P; Pyörälä T; Terho J; Toivonen J; Batar I; Lampe L; Andersson K
Contraception; 1987 Aug; 36(2):169-79. PubMed ID: 3123132
[TBL] [Abstract][Full Text] [Related]
19. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
[TBL] [Abstract][Full Text] [Related]
20. Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons.
Saloranta TH; Gyllenberg FK; But A; Gissler M; Laine MK; Heikinheimo O
Am J Obstet Gynecol; 2020 Dec; 223(6):886.e1-886.e17. PubMed ID: 32562657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
